huge disconnect between price and value, page-2

H Hall appears to back its judgements with significant trading action .
In the case of the previously named Clinical Cell Culture they exited en masse, but in the case of Sirtex they have bought en masse .

If a takeover offer were made, I don't think there is any certainty that major holders would not accept . "A bird in the hand is worth two in the bush" potentially .
If an offer of half of $1.5 billion happened I am pretty certain I would accept, and judging by CBA nominee behaviour I hypothesize they would also accept . Even an unsuccessful bid could potentially net a predator a significant stake for a future subsequent bid .